世界のヘモグロビン症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Hemoglobinopathy Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5773 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、ヘモグロビン症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ヒドロキシウレア、グルタミン、ジンテグロ、その他）、用途別市場規模（鎌状赤血球症、サラセミア）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・ヘモグロビン症治療薬の市場動向 ・企業の競争状況、市場シェア ・ヘモグロビン症治療薬の種類別市場規模と予測2016-2027（ヒドロキシウレア、グルタミン、ジンテグロ、その他） ・ヘモグロビン症治療薬の用途別市場規模と予測2016-2027（鎌状赤血球症、サラセミア） ・ヘモグロビン症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・ヘモグロビン症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・ヘモグロビン症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ヘモグロビン症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・ヘモグロビン症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novartis、AstraZeneca、Bluebird、Bristol-Myers Squibb、Emmaus Medical、Acceleron Pharma、HemaQuest Pharmaceuticals、Eli Lilly and Company、Celgene） ・結論

Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. 

Market Analysis and Insights: Global Hemoglobinopathy Drugs Market
The global Hemoglobinopathy Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Hemoglobinopathy Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Hemoglobinopathy Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hemoglobinopathy Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hemoglobinopathy Drugs market.

Global Hemoglobinopathy Drugs Scope and Market Size
Hemoglobinopathy Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hemoglobinopathy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Hydroxyurea
Glutamine
Zynteglo
Other

Segment by Application
Sickle Cell Diseases
Thalassemia

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
AstraZeneca
Bluebird
Bristol-Myers Squibb
Emmaus Medical
Acceleron Pharma
HemaQuest Pharmaceuticals
Eli Lilly and Company
Celgene

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemoglobinopathy Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Hydroxyurea
1.2.3 Glutamine
1.2.4 Zynteglo
1.2.5 Other
1.3 Market by Application
1.3.1 Global Hemoglobinopathy Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Sickle Cell Diseases
1.3.3 Thalassemia
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Hemoglobinopathy Drugs Market Perspective (2016-2027)
2.2 Hemoglobinopathy Drugs Growth Trends by Regions
2.2.1 Hemoglobinopathy Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Hemoglobinopathy Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Hemoglobinopathy Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Hemoglobinopathy Drugs Industry Dynamic
2.3.1 Hemoglobinopathy Drugs Market Trends
2.3.2 Hemoglobinopathy Drugs Market Drivers
2.3.3 Hemoglobinopathy Drugs Market Challenges
2.3.4 Hemoglobinopathy Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Hemoglobinopathy Drugs Players by Revenue
3.1.1 Global Top Hemoglobinopathy Drugs Players by Revenue (2016-2021)
3.1.2 Global Hemoglobinopathy Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Hemoglobinopathy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hemoglobinopathy Drugs Revenue
3.4 Global Hemoglobinopathy Drugs Market Concentration Ratio
3.4.1 Global Hemoglobinopathy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemoglobinopathy Drugs Revenue in 2020
3.5 Hemoglobinopathy Drugs Key Players Head office and Area Served
3.6 Key Players Hemoglobinopathy Drugs Product Solution and Service
3.7 Date of Enter into Hemoglobinopathy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Hemoglobinopathy Drugs Breakdown Data by Type
4.1 Global Hemoglobinopathy Drugs Historic Market Size by Type (2016-2021)
4.2 Global Hemoglobinopathy Drugs Forecasted Market Size by Type (2022-2027)

5 Hemoglobinopathy Drugs Breakdown Data by Application
5.1 Global Hemoglobinopathy Drugs Historic Market Size by Application (2016-2021)
5.2 Global Hemoglobinopathy Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Hemoglobinopathy Drugs Market Size (2016-2027)
6.2 North America Hemoglobinopathy Drugs Market Size by Type
6.2.1 North America Hemoglobinopathy Drugs Market Size by Type (2016-2021)
6.2.2 North America Hemoglobinopathy Drugs Market Size by Type (2022-2027)
6.2.3 North America Hemoglobinopathy Drugs Market Size by Type (2016-2027)
6.3 North America Hemoglobinopathy Drugs Market Size by Application
6.3.1 North America Hemoglobinopathy Drugs Market Size by Application (2016-2021)
6.3.2 North America Hemoglobinopathy Drugs Market Size by Application (2022-2027)
6.3.3 North America Hemoglobinopathy Drugs Market Size by Application (2016-2027)
6.4 North America Hemoglobinopathy Drugs Market Size by Country
6.4.1 North America Hemoglobinopathy Drugs Market Size by Country (2016-2021)
6.4.2 North America Hemoglobinopathy Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Hemoglobinopathy Drugs Market Size (2016-2027)
7.2 Europe Hemoglobinopathy Drugs Market Size by Type
7.2.1 Europe Hemoglobinopathy Drugs Market Size by Type (2016-2021)
7.2.2 Europe Hemoglobinopathy Drugs Market Size by Type (2022-2027)
7.2.3 Europe Hemoglobinopathy Drugs Market Size by Type (2016-2027)
7.3 Europe Hemoglobinopathy Drugs Market Size by Application
7.3.1 Europe Hemoglobinopathy Drugs Market Size by Application (2016-2021)
7.3.2 Europe Hemoglobinopathy Drugs Market Size by Application (2022-2027)
7.3.3 Europe Hemoglobinopathy Drugs Market Size by Application (2016-2027)
7.4 Europe Hemoglobinopathy Drugs Market Size by Country
7.4.1 Europe Hemoglobinopathy Drugs Market Size by Country (2016-2021)
7.4.2 Europe Hemoglobinopathy Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Hemoglobinopathy Drugs Market Size (2016-2027)
8.2 Asia-Pacific Hemoglobinopathy Drugs Market Size by Type
8.2.1 Asia-Pacific Hemoglobinopathy Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Hemoglobinopathy Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Hemoglobinopathy Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Hemoglobinopathy Drugs Market Size by Application
8.3.1 Asia-Pacific Hemoglobinopathy Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Hemoglobinopathy Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Hemoglobinopathy Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Hemoglobinopathy Drugs Market Size by Region
8.4.1 Asia-Pacific Hemoglobinopathy Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Hemoglobinopathy Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Hemoglobinopathy Drugs Market Size (2016-2027)
9.2 Latin America Hemoglobinopathy Drugs Market Size by Type
9.2.1 Latin America Hemoglobinopathy Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Hemoglobinopathy Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Hemoglobinopathy Drugs Market Size by Type (2016-2027)
9.3 Latin America Hemoglobinopathy Drugs Market Size by Application
9.3.1 Latin America Hemoglobinopathy Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Hemoglobinopathy Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Hemoglobinopathy Drugs Market Size by Application (2016-2027)
9.4 Latin America Hemoglobinopathy Drugs Market Size by Country
9.4.1 Latin America Hemoglobinopathy Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Hemoglobinopathy Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Hemoglobinopathy Drugs Market Size (2016-2027)
10.2 Middle East & Africa Hemoglobinopathy Drugs Market Size by Type
10.2.1 Middle East & Africa Hemoglobinopathy Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Hemoglobinopathy Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Hemoglobinopathy Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Hemoglobinopathy Drugs Market Size by Application
10.3.1 Middle East & Africa Hemoglobinopathy Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Hemoglobinopathy Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Hemoglobinopathy Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Hemoglobinopathy Drugs Market Size by Country
10.4.1 Middle East & Africa Hemoglobinopathy Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Hemoglobinopathy Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Hemoglobinopathy Drugs Introduction
11.1.4 Novartis Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Hemoglobinopathy Drugs Introduction
11.2.4 AstraZeneca Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.2.5 AstraZeneca Recent Development
11.3 Bluebird
11.3.1 Bluebird Company Details
11.3.2 Bluebird Business Overview
11.3.3 Bluebird Hemoglobinopathy Drugs Introduction
11.3.4 Bluebird Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.3.5 Bluebird Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Hemoglobinopathy Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Emmaus Medical
11.5.1 Emmaus Medical Company Details
11.5.2 Emmaus Medical Business Overview
11.5.3 Emmaus Medical Hemoglobinopathy Drugs Introduction
11.5.4 Emmaus Medical Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.5.5 Emmaus Medical Recent Development
11.6 Acceleron Pharma
11.6.1 Acceleron Pharma Company Details
11.6.2 Acceleron Pharma Business Overview
11.6.3 Acceleron Pharma Hemoglobinopathy Drugs Introduction
11.6.4 Acceleron Pharma Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.6.5 Acceleron Pharma Recent Development
11.7 HemaQuest Pharmaceuticals
11.7.1 HemaQuest Pharmaceuticals Company Details
11.7.2 HemaQuest Pharmaceuticals Business Overview
11.7.3 HemaQuest Pharmaceuticals Hemoglobinopathy Drugs Introduction
11.7.4 HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.7.5 HemaQuest Pharmaceuticals Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Hemoglobinopathy Drugs Introduction
11.8.4 Eli Lilly and Company Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.8.5 Eli Lilly and Company Recent Development
11.9 Celgene
11.9.1 Celgene Company Details
11.9.2 Celgene Business Overview
11.9.3 Celgene Hemoglobinopathy Drugs Introduction
11.9.4 Celgene Revenue in Hemoglobinopathy Drugs Business (2016-2021)
11.9.5 Celgene Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hemoglobinopathy Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Hydroxyurea
Table 3. Key Players of Glutamine
Table 4. Key Players of Zynteglo
Table 5. Key Players of Other
Table 6. Global Hemoglobinopathy Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Hemoglobinopathy Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Hemoglobinopathy Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Hemoglobinopathy Drugs Market Share by Regions (2016-2021)
Table 10. Global Hemoglobinopathy Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Hemoglobinopathy Drugs Market Share by Regions (2022-2027)
Table 12. Hemoglobinopathy Drugs Market Trends
Table 13. Hemoglobinopathy Drugs Market Drivers
Table 14. Hemoglobinopathy Drugs Market Challenges
Table 15. Hemoglobinopathy Drugs Market Restraints
Table 16. Global Hemoglobinopathy Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Hemoglobinopathy Drugs Market Share by Players (2016-2021)
Table 18. Global Top Hemoglobinopathy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemoglobinopathy Drugs as of 2020)
Table 19. Ranking of Global Top Hemoglobinopathy Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Hemoglobinopathy Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Hemoglobinopathy Drugs Product Solution and Service
Table 23. Date of Enter into Hemoglobinopathy Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Hemoglobinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Hemoglobinopathy Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Hemoglobinopathy Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Hemoglobinopathy Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Hemoglobinopathy Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Hemoglobinopathy Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Hemoglobinopathy Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Hemoglobinopathy Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Hemoglobinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Hemoglobinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Hemoglobinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Hemoglobinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Hemoglobinopathy Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Hemoglobinopathy Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Hemoglobinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Hemoglobinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Hemoglobinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Hemoglobinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Hemoglobinopathy Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Hemoglobinopathy Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Hemoglobinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Hemoglobinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Hemoglobinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Hemoglobinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Hemoglobinopathy Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Hemoglobinopathy Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Hemoglobinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Hemoglobinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Hemoglobinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Hemoglobinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Hemoglobinopathy Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Hemoglobinopathy Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Hemoglobinopathy Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Hemoglobinopathy Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Hemoglobinopathy Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Hemoglobinopathy Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Hemoglobinopathy Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Hemoglobinopathy Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. Novartis Company Details
Table 64. Novartis Business Overview
Table 65. Novartis Hemoglobinopathy Drugs Product
Table 66. Novartis Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 67. Novartis Recent Development
Table 68. AstraZeneca Company Details
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Hemoglobinopathy Drugs Product
Table 71. AstraZeneca Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 72. AstraZeneca Recent Development
Table 73. Bluebird Company Details
Table 74. Bluebird Business Overview
Table 75. Bluebird Hemoglobinopathy Drugs Product
Table 76. Bluebird Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 77. Bluebird Recent Development
Table 78. Bristol-Myers Squibb Company Details
Table 79. Bristol-Myers Squibb Business Overview
Table 80. Bristol-Myers Squibb Hemoglobinopathy Drugs Product
Table 81. Bristol-Myers Squibb Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 82. Bristol-Myers Squibb Recent Development
Table 83. Emmaus Medical Company Details
Table 84. Emmaus Medical Business Overview
Table 85. Emmaus Medical Hemoglobinopathy Drugs Product
Table 86. Emmaus Medical Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 87. Emmaus Medical Recent Development
Table 88. Acceleron Pharma Company Details
Table 89. Acceleron Pharma Business Overview
Table 90. Acceleron Pharma Hemoglobinopathy Drugs Product
Table 91. Acceleron Pharma Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 92. Acceleron Pharma Recent Development
Table 93. HemaQuest Pharmaceuticals Company Details
Table 94. HemaQuest Pharmaceuticals Business Overview
Table 95. HemaQuest Pharmaceuticals Hemoglobinopathy Drugs Product
Table 96. HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 97. HemaQuest Pharmaceuticals Recent Development
Table 98. Eli Lilly and Company Company Details
Table 99. Eli Lilly and Company Business Overview
Table 100. Eli Lilly and Company Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 101. Eli Lilly and Company Recent Development
Table 102. Celgene Company Details
Table 103. Celgene Business Overview
Table 104. Celgene Hemoglobinopathy Drugs Product
Table 105. Celgene Revenue in Hemoglobinopathy Drugs Business (2016-2021) & (US$ Million)
Table 106. Celgene Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hemoglobinopathy Drugs Market Share by Type: 2020 VS 2027
Figure 2. Hydroxyurea Features
Figure 3. Glutamine Features
Figure 4. Zynteglo Features
Figure 5. Other Features
Figure 6. Global Hemoglobinopathy Drugs Market Share by Application: 2020 VS 2027
Figure 7. Sickle Cell Diseases Case Studies
Figure 8. Thalassemia Case Studies
Figure 9. Hemoglobinopathy Drugs Report Years Considered
Figure 10. Global Hemoglobinopathy Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Hemoglobinopathy Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Hemoglobinopathy Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global Hemoglobinopathy Drugs Market Share by Regions (2022-2027)
Figure 14. Global Hemoglobinopathy Drugs Market Share by Players in 2020
Figure 15. Global Top Hemoglobinopathy Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemoglobinopathy Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Hemoglobinopathy Drugs Revenue in 2020
Figure 17. Global Hemoglobinopathy Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global Hemoglobinopathy Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Hemoglobinopathy Drugs Market Share by Type (2016-2027)
Figure 21. North America Hemoglobinopathy Drugs Market Share by Application (2016-2027)
Figure 22. North America Hemoglobinopathy Drugs Market Share by Country (2016-2027)
Figure 23. United States Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Hemoglobinopathy Drugs Market Share by Type (2016-2027)
Figure 27. Europe Hemoglobinopathy Drugs Market Share by Application (2016-2027)
Figure 28. Europe Hemoglobinopathy Drugs Market Share by Country (2016-2027)
Figure 29. Germany Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Hemoglobinopathy Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Hemoglobinopathy Drugs Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Hemoglobinopathy Drugs Market Share by Region (2016-2027)
Figure 39. China Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Hemoglobinopathy Drugs Market Share by Type (2016-2027)
Figure 47. Latin America Hemoglobinopathy Drugs Market Share by Application (2016-2027)
Figure 48. Latin America Hemoglobinopathy Drugs Market Share by Country (2016-2027)
Figure 49. Mexico Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Hemoglobinopathy Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Hemoglobinopathy Drugs Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Hemoglobinopathy Drugs Market Share by Country (2016-2027)
Figure 55. Turkey Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Hemoglobinopathy Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Novartis Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 59. AstraZeneca Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 60. Bluebird Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 62. Emmaus Medical Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 63. Acceleron Pharma Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 64. HemaQuest Pharmaceuticals Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 65. Eli Lilly and Company Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 66. Celgene Revenue Growth Rate in Hemoglobinopathy Drugs Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---